River Plate/Alcon's dry eye treatment needs more study, US panel says
This article was originally published in Scrip
The efficacy of River Plate Biotechnology/Alcon's dry eye treatment Rejena (sodium hyaluronate ophthalmic solution, 0.18%) requires further study before approval, the US FDA's dermatologic and ophthalmic drugs advisory panel has recommended.
You may also be interested in...
Pink Sheet reporter and editors discuss whether emotion could be removed from US FDA advisory committees, adverse events and advancing science in gene therapy development, and Capitol Hill’s interest in the ongoing user fee negotiations.
Recent adverse events are ‘speed bumps’ that need to be worked around, biologics center head Peter Marks says; Morgan Stanley’s Peter Hwang asserts high-profile safety issues have added to unpredictability of gene therapy development, dampening investor enthusiasm for the field.
Cellular responses and other potential immune correlates of protection could be better measurements of efficacy, Janssen’s vaccine discovery head argues at BIO.